Simplify Logo
Sanofi

Sanofi

Global pharma company; vaccines and R&D

Maintenance and Digital Transformation Intern

InternshipDeadline 12/9/26
No salary listed
Bachelor's
Aramon, France
In Person

About the job

Requirements
  • A Bac+5 degree in computer science, information systems, or data.
  • Proficiency in Power BI and Microsoft Excel.
  • Knowledge of SAP and Power Studio.
  • Basic knowledge of JavaScript.
  • Ability to read English.
  • Strong interpersonal skills, rigor, and analytical ability.
Responsibilities
  • Participate in the maintenance, evolution, and support of the information technology tools used by the team, including enterprise resource planning systems, reporting tools, and dashboards.
  • Support the development of automation solutions to make planning processes more reliable and faster.
  • Contribute to data exploitation and visualization to facilitate decision-making.
  • Help identify process-improvement opportunities and propose innovative solutions in collaboration with business teams.
  • Contribute to writing and updating procedures and guides related to digital tools.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Belén Garijo upgraded 2026 guidance on July 30 after strong Dupixent and new approvals.
  • Paulo Fontoura starts September 1, 2026, sharpening R&D execution under a pipeline reset.
  • Tzield, Wayrilz, Cenrifki, and Sarclisa approvals broaden growth beyond Dupixent in 2026.

What critics are saying

  • Dupixent drove Q2 2026 sales, exposing Sanofi to patent expiry after 2030.
  • Sanofi killed amlitelimab and itepekimab in 2026, signaling a fragile late-stage pipeline.
  • Texas sued Sanofi on February 19, 2026; adverse judgments could multiply commercialization costs.

What makes Sanofi unique

  • Dupixent and vaccines give Sanofi global scale across immunology, respiratory, and prevention.
  • Sarclisa Escena won FDA approval July 10, 2026 as first on-body injector cancer therapy.
  • Frankfurt insulin manufacturing secures European supply, backed by €400 million German aid September 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Electra Therapeutics
Sep 11th, 2026
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.